Triple Threat: Full Rhinosinusitis Data Place Dupixent Top Of The IL Heap
Sanofi and Regeneron take a big step forward to building an allergy franchise off the back of newly released data from latest Dupixent trials in severe chronic rhinosinusitis with nasal polyps.
You may also be interested in...
The new indication represents the third one for Sanofi/Regeneron's IL-4/IL-13 inhibitor, after atopic dermatitis and moderate to severe asthma.
User fee goal date calendar for June includes AMAG’s female sexual dysfunction drug Vyleesi, new indications for Sanofi/Regeneron’s Dupixent in rhinosinusitis and Merck’s Zerbaxa in nosocomial pneumonia.
Sales of Praluent and Eloctate disappointed but the promise of further growth for big-selling Dupixent augurs well for the French firm's future.